vs
Side-by-side financial comparison of ARDELYX, INC. (ARDX) and CLPS Inc (CLPS). Click either name above to swap in a different company.
ARDELYX, INC. is the larger business by last-quarter revenue ($125.2M vs $82.8M, roughly 1.5× CLPS Inc).
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
CLPS Inc is a global information technology, consulting and digital solutions provider primarily serving the financial services sector, including banking, insurance and asset management clients. It also offers tailored tech solutions for retail, healthcare and e-commerce segments, with operating footprints across North America, Asia Pacific and Europe.
ARDX vs CLPS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $125.2M | $82.8M |
| Net Profit | — | $183.0K |
| Gross Margin | — | 23.1% |
| Operating Margin | — | 0.2% |
| Net Margin | — | 0.2% |
| Revenue YoY | 7.8% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $82.8M | ||
| Q1 26 | $125.2M | — | ||
| Q4 25 | $125.2M | — | ||
| Q3 25 | $110.3M | — | ||
| Q2 25 | $97.7M | — | ||
| Q1 25 | $74.1M | — | ||
| Q4 24 | $116.1M | $71.8M | ||
| Q3 24 | $98.2M | — |
| Q2 26 | — | $183.0K | ||
| Q1 26 | — | — | ||
| Q4 25 | $-407.0K | — | ||
| Q3 25 | $-969.0K | — | ||
| Q2 25 | $-19.1M | — | ||
| Q1 25 | $-41.1M | — | ||
| Q4 24 | $4.6M | $-993.5K | ||
| Q3 24 | $-809.0K | — |
| Q2 26 | — | 23.1% | ||
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | 21.9% | ||
| Q3 24 | 84.0% | — |
| Q2 26 | — | 0.2% | ||
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | -14.7% | — | ||
| Q1 25 | -49.0% | — | ||
| Q4 24 | 7.0% | -1.3% | ||
| Q3 24 | 2.3% | — |
| Q2 26 | — | 0.2% | ||
| Q1 26 | — | — | ||
| Q4 25 | -0.3% | — | ||
| Q3 25 | -0.9% | — | ||
| Q2 25 | -19.5% | — | ||
| Q1 25 | -55.5% | — | ||
| Q4 24 | 4.0% | -1.4% | ||
| Q3 24 | -0.8% | — |
| Q2 26 | — | — | ||
| Q1 26 | $0.00 | — | ||
| Q4 25 | $-0.01 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.08 | — | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $264.7M | $29.1M |
| Total DebtLower is stronger | $202.8M | — |
| Stockholders' EquityBook value | $166.9M | $57.6M |
| Total Assets | $501.6M | $118.1M |
| Debt / EquityLower = less leverage | 1.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $29.1M | ||
| Q1 26 | $264.7M | — | ||
| Q4 25 | $68.0M | — | ||
| Q3 25 | $42.7M | — | ||
| Q2 25 | $90.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $64.9M | $31.2M | ||
| Q3 24 | $47.4M | — |
| Q2 26 | — | — | ||
| Q1 26 | $202.8M | — | ||
| Q4 25 | $202.8M | — | ||
| Q3 25 | $202.1M | — | ||
| Q2 25 | $201.4M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | $150.9M | — | ||
| Q3 24 | $100.7M | — |
| Q2 26 | — | $57.6M | ||
| Q1 26 | $166.9M | — | ||
| Q4 25 | $166.9M | — | ||
| Q3 25 | $154.3M | — | ||
| Q2 25 | $139.5M | — | ||
| Q1 25 | $145.7M | — | ||
| Q4 24 | $173.3M | $63.9M | ||
| Q3 24 | $158.3M | — |
| Q2 26 | — | $118.1M | ||
| Q1 26 | $501.6M | — | ||
| Q4 25 | $501.6M | — | ||
| Q3 25 | $486.2M | — | ||
| Q2 25 | $466.8M | — | ||
| Q1 25 | $410.2M | — | ||
| Q4 24 | $435.8M | $110.0M | ||
| Q3 24 | $367.9M | — |
| Q2 26 | — | — | ||
| Q1 26 | 1.21× | — | ||
| Q4 25 | 1.21× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 1.04× | — | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 0.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARDX
| IBSRELA | $86.6M | 69% |
| XPHOZAH | $27.8M | 22% |
| Product supply revenue | $9.4M | 8% |
| Non-cash royalty revenue related to the sale of future royalties | $1.4M | 1% |
| Licensing revenue | $23.0K | 0% |
CLPS
Segment breakdown not available.
